---
layout: default
title: Silver
parent: Model Prediction Only (L5)
nav_order: 766
evidence_level: L5
indication_count: 10
---

# Silver
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Silver: From Unspecified Original Use to Bone Paget Disease

## One-Sentence Summary

> No original indication or mechanism-of-action data is currently on file for Silver (DrugBank DB12965).
> The TxGNN model's top prediction suggests possible relevance to **Bone Paget Disease**,
> but the underlying evidence — **2 clinical trials** and **5 publications** — consists entirely of unrelated "silver staining" histology methodology papers, not therapeutic studies of silver as a drug.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | No data available |
| Predicted New Indication | Bone Paget Disease |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a blocking-severity data gap, DG002). No original indications are recorded for Silver in this evidence pack, so no pharmacological rationale can be constructed linking a known original use to the predicted new indication.

More importantly, the evidence pack's own analysis flags this top prediction as a **likely false positive caused by a name collision**. All five supporting publications discuss "silver staining" (Ag-NOR staining), a laboratory histology technique used to visualize nucleolar organizer regions in osteoclast nuclei — a method for studying Paget's disease tissue samples, not a treatment involving silver compounds. The two supporting clinical trials (a general rare-disease patient registry and an unrelated phosphate-reduction dialysis trial) also show no connection to silver-based therapy for bone Paget disease.

This pattern recurs across several other top-ranked TxGNN predictions for this drug (e.g., amenorrhea, esotropia, myelodysplastic syndrome): the retrieved literature is dominated by unrelated hits on the surname "Silver" (e.g., researchers named Richard T. Silver, Silver-Russell syndrome) or histological silver-staining techniques, rather than genuine pharmacological evidence for elemental/ionic silver as a therapeutic agent. This strongly suggests a systematic entity-disambiguation issue rather than a substantive repurposing signal.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT01793168](https://clinicaltrials.gov/study/NCT01793168) | N/A | Recruiting | 20,000 | General rare-disease patient registry (Sanford CoRDS); not a silver-specific intervention trial |
| [NCT03573089](https://clinicaltrials.gov/study/NCT03573089) | N/A | Recruiting | 3,600 | Serum phosphate reduction trial in dialysis patients; no silver compound involved despite title association with Paget-related bone metabolism |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [9836854](https://pubmed.ncbi.nlm.nih.gov/9836854/) | 1998 | Mechanistic | Bone | Silver-staining (AgNOR) technique used to study osteoclast nucleoli in Paget's bone disease — a lab method, not a treatment study |
| [3163726](https://pubmed.ncbi.nlm.nih.gov/3163726/) | 1988 | Mechanistic | J Nucl Med | Gallium-67 citrate localization in osteoclast nuclei; silver not the subject drug |
| [4111887](https://pubmed.ncbi.nlm.nih.gov/4111887/) | 1972 | Method | Stain Technology | Silver staining of bone for osteoid quantification — histology method paper |
| [2420233](https://pubmed.ncbi.nlm.nih.gov/2420233/) | 1985 | Method | Anat Anz | Silver impregnation of bone tissue — histology staining method |
| [9227338](https://pubmed.ncbi.nlm.nih.gov/9227338/) | 1997 | Mechanistic | J Pathol | Vitamin D receptor mRNA quantification in bone/kidney tissue; unrelated to silver as therapy |

**Note:** None of the above papers evaluate silver compounds as a therapeutic intervention for bone Paget disease.

---

## India Market Information

Silver (DB12965) currently holds **no registered authorizations** in India (market status: Not Marketed; total registrations: 0). No product-level licensing data is available for review.

---

## Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction data are currently on file for this entry (DDI query status: not found).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked TxGNN prediction (Bone Paget Disease, score 99.67%) is supported only by histology-method literature about the "silver staining" laboratory technique, not by any evidence of silver as a therapeutic agent — this is assessed as a name-collision false positive (Evidence Level L5, Decision Stage S0). Combined with the absence of MOA data, original indication data, and any India market presence, there is no basis to advance this candidate.

**To proceed, the following is needed:**
- Resolve blocking data gap DG001 (TFDA/regulatory label warnings and contraindications)
- Obtain verified mechanism-of-action data for silver as a pharmacological agent (DG002)
- Re-run literature/trial retrieval with improved entity disambiguation (exclude "silver staining" methodology papers and author-surname matches)
- If a genuine indication is to be pursued, evaluate rank 7 (esophageal disease) separately, where two literature hits (systemic argyria toxicity case report; in vitro phosphino-silver complex cytotoxicity against esophageal cancer cells) show at least nominal silver-compound relevance — though still only preclinical/toxicity-level evidence (L4/S1), also currently rated Hold
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

